Skip to main content
Erschienen in: Diabetologia 11/2014

01.11.2014 | Article

Predicting major outcomes in type 1 diabetes: a model development and validation study

verfasst von: Sabita S. Soedamah-Muthu, Yvonne Vergouwe, Tina Costacou, Rachel G. Miller, Janice Zgibor, Nish Chaturvedi, Janet K. Snell-Bergeon, David M. Maahs, Marian Rewers, Carol Forsblom, Valma Harjutsalo, Per-Henrik Groop, John H. Fuller, Karel G. M. Moons, Trevor J. Orchard

Erschienen in: Diabetologia | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Type 1 diabetes is associated with a higher risk of major vascular complications and death. A reliable method that predicted these outcomes early in the disease process would help in risk classification. We therefore developed such a prognostic model and quantified its performance in independent cohorts.

Methods

Data were analysed from 1,973 participants with type 1 diabetes followed for 7 years in the EURODIAB Prospective Complications Study. Strong prognostic factors for major outcomes were combined in a Weibull regression model. The performance of the model was tested in three different prospective cohorts: the Pittsburgh Epidemiology of Diabetes Complications study (EDC, n = 554), the Finnish Diabetic Nephropathy study (FinnDiane, n = 2,999) and the Coronary Artery Calcification in Type 1 Diabetes study (CACTI, n = 580). Major outcomes included major CHD, stroke, end-stage renal failure, amputations, blindness and all-cause death.

Results

A total of 95 EURODIAB patients with type 1 diabetes developed major outcomes during follow-up. Prognostic factors were age, HbA1c, WHR, albumin/creatinine ratio and HDL-cholesterol level. The discriminative ability of the model was adequate, with a concordance statistic (C-statistic) of 0.74. Discrimination was similar or even better in the independent cohorts, the C-statistics being: EDC, 0.79; FinnDiane, 0.82; and CACTI, 0.73.

Conclusions/interpretation

Our prognostic model, which uses easily accessible clinical features can discriminate between type 1 diabetes patients who have a good or a poor prognosis. Such a prognostic model may be helpful in clinical practice and for risk stratification in clinical trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Stephenson J, Fuller JH (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef Stephenson J, Fuller JH (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef
2.
Zurück zum Zitat Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ (1991) Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 34:584–589PubMedCrossRef Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ (1991) Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 34:584–589PubMedCrossRef
3.
Zurück zum Zitat Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55:1463–1469PubMedCrossRef Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55:1463–1469PubMedCrossRef
4.
Zurück zum Zitat Ahola AJ, Saraheimo M, Forsblom C, Hietala K, Sintonen H, Groop P-H (2010) Health-related quality of life in patients with type 1 diabetes—association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant 25:1903–1908PubMedCrossRef Ahola AJ, Saraheimo M, Forsblom C, Hietala K, Sintonen H, Groop P-H (2010) Health-related quality of life in patients with type 1 diabetes—association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant 25:1903–1908PubMedCrossRef
5.
Zurück zum Zitat Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the General Practice Research Database. Diabetes Care 29:798–804PubMedCrossRef Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the General Practice Research Database. Diabetes Care 29:798–804PubMedCrossRef
6.
Zurück zum Zitat Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321PubMedCrossRefPubMedCentral Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321PubMedCrossRefPubMedCentral
7.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRef
8.
Zurück zum Zitat Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef
9.
Zurück zum Zitat Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med 169:1307–1316PubMedCrossRefPubMedCentral Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med 169:1307–1316PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Nathan DM (2012) Understanding the long-term benefits and dangers of intensive therapy of diabetes. Arch Intern Med 172:769–770PubMedCrossRef Nathan DM (2012) Understanding the long-term benefits and dangers of intensive therapy of diabetes. Arch Intern Med 172:769–770PubMedCrossRef
11.
Zurück zum Zitat Davis WA, Davis TME (2010) Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 90:e75–e78PubMedCrossRef Davis WA, Davis TME (2010) Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 90:e75–e78PubMedCrossRef
12.
Zurück zum Zitat Zgibor JC, Ruppert K, Orchard TJ et al (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 88:314–321PubMedCrossRefPubMedCentral Zgibor JC, Ruppert K, Orchard TJ et al (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 88:314–321PubMedCrossRefPubMedCentral
13.
Zurück zum Zitat Groop P-H, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMedCrossRefPubMedCentral Groop P-H, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMedCrossRefPubMedCentral
14.
Zurück zum Zitat Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697PubMedCrossRef Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697PubMedCrossRef
15.
Zurück zum Zitat Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116–1124PubMedCrossRef Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116–1124PubMedCrossRef
16.
Zurück zum Zitat Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024PubMedCrossRef Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024PubMedCrossRef
17.
Zurück zum Zitat Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Diabetes 52:2833–2839PubMedCrossRef Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Diabetes 52:2833–2839PubMedCrossRef
18.
Zurück zum Zitat Soedamah-Muthu SS, Chaturvedi N, Toeller M et al (2004) Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27:530–537PubMedCrossRef Soedamah-Muthu SS, Chaturvedi N, Toeller M et al (2004) Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 27:530–537PubMedCrossRef
19.
Zurück zum Zitat Sjolie AK, Stephenson J, Aldington S et al (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104:252–260PubMedCrossRef Sjolie AK, Stephenson J, Aldington S et al (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104:252–260PubMedCrossRef
20.
Zurück zum Zitat Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef
21.
22.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
23.
Zurück zum Zitat Rubin DB, Schenker N (1991) Multiple imputation in health-care databases: an overview and some applications. Stat Med 10:585–598PubMedCrossRef Rubin DB, Schenker N (1991) Multiple imputation in health-care databases: an overview and some applications. Stat Med 10:585–598PubMedCrossRef
24.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRef
25.
Zurück zum Zitat Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942PubMedCrossRef Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942PubMedCrossRef
26.
Zurück zum Zitat Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546PubMedCrossRef Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546PubMedCrossRef
27.
Zurück zum Zitat Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248–1254PubMedCrossRef Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248–1254PubMedCrossRef
28.
Zurück zum Zitat Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef
29.
Zurück zum Zitat Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
30.
Zurück zum Zitat Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedCrossRef Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMedCrossRef
31.
Zurück zum Zitat Game FL, Jones AF (2001) Coronary heart disease risk assessment in diabetes mellitus—a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 18:355–359PubMedCrossRef Game FL, Jones AF (2001) Coronary heart disease risk assessment in diabetes mellitus—a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 18:355–359PubMedCrossRef
32.
Zurück zum Zitat Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K (2001) A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 8:291–297PubMedCrossRef Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K (2001) A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score. J Cardiovasc Risk 8:291–297PubMedCrossRef
33.
Zurück zum Zitat Kaptoge S, Di Angelantonio E, Pennells L et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320PubMedCrossRef Kaptoge S, Di Angelantonio E, Pennells L et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320PubMedCrossRef
34.
Zurück zum Zitat Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD (2004) Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23:2567–2586PubMedCrossRef Steyerberg EW, Borsboom GJ, van Houwelingen HC, Eijkemans MJ, Habbema JD (2004) Validation and updating of predictive logistic regression models: a study on sample size and shrinkage. Stat Med 23:2567–2586PubMedCrossRef
35.
Zurück zum Zitat Steyerberg EW (2005) Local applicability of clinical and model-based probability estimates. Med Decis Mak 25:678–680CrossRef Steyerberg EW (2005) Local applicability of clinical and model-based probability estimates. Med Decis Mak 25:678–680CrossRef
36.
Zurück zum Zitat Tielemans SM, Soedamah-Muthu SS, de Neve M et al (2013) Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 56:82–91PubMedCrossRef Tielemans SM, Soedamah-Muthu SS, de Neve M et al (2013) Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 56:82–91PubMedCrossRef
37.
Zurück zum Zitat Delahanty LM, Nathan DM, Lachin JM et al (2009) Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 89:518–524PubMedCrossRefPubMedCentral Delahanty LM, Nathan DM, Lachin JM et al (2009) Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. Am J Clin Nutr 89:518–524PubMedCrossRefPubMedCentral
38.
Zurück zum Zitat Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473PubMedCrossRef Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473PubMedCrossRef
39.
Zurück zum Zitat Choi SC (1998) Sample size in clinical trials with dichotomous endpoints: use of covariables. J Biopharm Stat 8:367–375PubMedCrossRef Choi SC (1998) Sample size in clinical trials with dichotomous endpoints: use of covariables. J Biopharm Stat 8:367–375PubMedCrossRef
40.
Zurück zum Zitat Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C (2003) Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289:2554–2559PubMedCrossRef Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C (2003) Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289:2554–2559PubMedCrossRef
41.
Zurück zum Zitat Rosenson RS, Fioretto P, Dodson PM (2011) Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218:13–18PubMedCrossRef Rosenson RS, Fioretto P, Dodson PM (2011) Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis 218:13–18PubMedCrossRef
42.
Zurück zum Zitat Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77:S26–S30PubMedCrossRef Nishikawa T, Edelstein D, Brownlee M (2000) The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 77:S26–S30PubMedCrossRef
43.
Zurück zum Zitat Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef
44.
Zurück zum Zitat Tanaka S, Tanaka S, Iimuro S et al (2013) Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 36:1193–1199PubMedCrossRefPubMedCentral Tanaka S, Tanaka S, Iimuro S et al (2013) Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 36:1193–1199PubMedCrossRefPubMedCentral
Metadaten
Titel
Predicting major outcomes in type 1 diabetes: a model development and validation study
verfasst von
Sabita S. Soedamah-Muthu
Yvonne Vergouwe
Tina Costacou
Rachel G. Miller
Janice Zgibor
Nish Chaturvedi
Janet K. Snell-Bergeon
David M. Maahs
Marian Rewers
Carol Forsblom
Valma Harjutsalo
Per-Henrik Groop
John H. Fuller
Karel G. M. Moons
Trevor J. Orchard
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 11/2014
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3358-x

Weitere Artikel der Ausgabe 11/2014

Diabetologia 11/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.